[go: up one dir, main page]

AR054710A1 - Formulacion de proteinas mutadas de staphylococcal enterotoxina c1 (sec1) y metodo para su formulacion - Google Patents

Formulacion de proteinas mutadas de staphylococcal enterotoxina c1 (sec1) y metodo para su formulacion

Info

Publication number
AR054710A1
AR054710A1 ARP050105011A ARP050105011A AR054710A1 AR 054710 A1 AR054710 A1 AR 054710A1 AR P050105011 A ARP050105011 A AR P050105011A AR P050105011 A ARP050105011 A AR P050105011A AR 054710 A1 AR054710 A1 AR 054710A1
Authority
AR
Argentina
Prior art keywords
formulation
sec1
mutant protein
mastitis
effects
Prior art date
Application number
ARP050105011A
Other languages
English (en)
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of AR054710A1 publication Critical patent/AR054710A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulacion de una proteína mutante de SEC1, una toxina de Staphylococcus aureus, que presenta efectos en la prevencion, alivio de síntomas y tratamiento de la mastitis mediante una funcion inmune mejorada de las vacas lecheras lactantes y no lactantes, que comprende micropartículas solidas que contienen a la proteína mutante de SEC1 como ingrediente activo, un excipiente estabilizador de la proteína, un excipiente auxiliar a base de carbohidrato, y un material lipofílico, dispersados en un aceite biocompatible y/o en un compuesto a base de éster de ácido graso. La formulacion es capaz de lograr una administracion in vivo efectiva de una proteína mutante soluble en agua que constituye un ingrediente activo mientras que mantiene su actividad. Además, la formulacion presenta efectos terapéuticos en la prevencion y en el tratamiento de la mastitis mediante efectos de inmunpotenciacion debido a la capacidad superior de produccion de anticuerpos cuando se administra a vacas lecheras. Además, la formulacion se puede utilizar como prepararcion inyectable.
ARP050105011A 2004-12-01 2005-11-30 Formulacion de proteinas mutadas de staphylococcal enterotoxina c1 (sec1) y metodo para su formulacion AR054710A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20040099624 2004-12-01

Publications (1)

Publication Number Publication Date
AR054710A1 true AR054710A1 (es) 2007-07-11

Family

ID=36565261

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105011A AR054710A1 (es) 2004-12-01 2005-11-30 Formulacion de proteinas mutadas de staphylococcal enterotoxina c1 (sec1) y metodo para su formulacion

Country Status (5)

Country Link
KR (1) KR100729954B1 (es)
AR (1) AR054710A1 (es)
MY (1) MY140503A (es)
PE (1) PE20061171A1 (es)
WO (1) WO2006059846A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2547361T1 (sl) 2010-03-17 2021-01-29 SOCPRA - Sceiences et Genie, s.e.c. Bakterijske komponente cepiva iz staphylococcus aureus in njihova uporaba
JP7181208B2 (ja) 2016-10-21 2022-11-30 ソクプラ、サイエンシズ、エ、ジェニ、エス．イー．シー． ワクチン構築物およびブドウ球菌感染症に対するその使用
KR102061735B1 (ko) * 2018-06-08 2020-01-02 대한민국(농림축산식품부 농림축산검역본부장) 황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
DK1071407T3 (da) * 1999-01-18 2014-10-20 Lg Life Sciences Ltd Lipofile mikropartikler indeholdende et proteinlægemiddel eller et antigen og formulering omhandlende samme
WO2001087270A2 (en) 2000-05-12 2001-11-22 Pharmacia & Upjohn Company Vaccine composition, method of preparing the same, and method of vaccinating vertebrates

Also Published As

Publication number Publication date
MY140503A (en) 2009-12-31
KR100729954B1 (ko) 2007-06-20
PE20061171A1 (es) 2006-12-18
WO2006059846A1 (en) 2006-06-08
KR20060061225A (ko) 2006-06-07

Similar Documents

Publication Publication Date Title
MX395136B (es) Composiciones farmaceuticas y metodos de administracion relacionados.
TR201808178T4 (tr) Aktif ajanların transdermal dağıtımı için bileşimler.
PT109395B (pt) Composições veterinárias orais parasiticidas compreendendo agentes activos de actuação sistémica, métodos e as suas utilizações
TR200003158T2 (tr) Jelleşebilen farmasötik bileşimler
ATE332138T1 (de) Flibanserin zur behandlung extrapyramidaler bewegungsstörungen
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
EA201101706A1 (ru) Лекарственное средство на основе дииндолилметана(dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
JP2016539921A5 (es)
EP1852114A4 (en) COMPOSITION WITH DIHOMO (GAMMA) LINE ACIDIC ACID (DGLA) AS AN ACTIVE INGREDIENTS
EA201270615A1 (ru) Противогрибковый препарат, содержащий грибковый организм
BRPI0510449A (pt) uso de formulações de meloxicam em medicina veterinária
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
KR20130044330A (ko) 사상충 체내 감염증을 조절하기 위한 조성물
TW200600121A (en) Pharmaceutical dosage forms
RU2414221C2 (ru) Фармацевтическая композиция на основе циклоферона местного и наружного применения для лечения гнойно-деструктивных поражений слизистой и кожи, общесистемных заболеваний при иммунодефицитных состояниях
AR054710A1 (es) Formulacion de proteinas mutadas de staphylococcal enterotoxina c1 (sec1) y metodo para su formulacion
EP2982369A1 (en) Preparation for treating equine inflammation
FR2887150B1 (fr) Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
JP2010534221A (ja) ライム病の予防用の局所抗生物質組成物
MX2023010847A (es) Formulaciones de tasipimidina y uso de las mismas.
ATE457721T1 (de) An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen
Mishra An investigation on the approach to target lipopolysaccharide through polymeric capped nano-structured formulation for the management of sepsis
Chhabra et al. Sarcoptic mange in domestic animals and human scabies in India

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal